No Data
Dashanlin: Dashanlin Pharmaceutical Group Co., Ltd. Third Quarter Report 2024
Announcement of Dashenlin Pharmaceutical Group Co., Ltd. on the main operating data for the third quarter of 2024
Dashenlin Pharmaceutical Group Co., Ltd. Report for the third quarter of 2024
dashenlin pharmaceutical group (603233.SH): The net income in the third quarter was 0.201 billion yuan, a decrease of 21.95% year-on-year.
On October 30, Gelonhui announced that dashenlin pharmaceutical group (603233.SH) achieved revenue of 19.731 billion yuan in the first three quarters of 2024, an 11.33% year-on-year increase; net income attributable to shareholders of the listed company was 0.858 billion yuan, a 26.93% year-on-year decrease, with a basic earnings per share of 0.75 yuan. In the third quarter of 2024, revenue reached 6.386 billion yuan, up 11.42% year-on-year; net income attributable to shareholders of the listed company was 0.201 billion yuan, down 21.95% year-on-year, with basic earnings per share of 0.18 yuan.
DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
dashenlin pharmaceutical group (603233.SH) implemented the distribution of equity for the first half of 2024: 0.31 yuan per share, with the equity registration on October 22nd.
dashenlin pharmaceutical group (603233.SH) issued the announcement of the implementation of the equity distribution for the first half of 2024, deducting the total share capital after repurchase...
No Data
No Data
